Yahoo Finance·2026-01-01 11:29Group 1 - BioMarin Pharmaceutical Inc. is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion, with a share price of $14.50 per Amicus share [2][3] - The acquisition is expected to close in Q2 2026, pending regulatory clearances and stockholder approval [2] - This strategic move is aimed at stabilizing long-term cash flows and expanding BioMarin's leadership in rare diseases by adding two marketed therapies for lysosomal storage disorders, which generated a combined revenue of $599 million over the last four quarters [3] Group 2 - H.C. Wainwright raised BioMarin's price target to $60 from $55, maintaining a Neutral rating, indicating that Voxzogo will remain the primary driver of stock value until peak sales materialize in the 2030s [1][3] - The acquisition includes US rights to DMX-200, a Phase 3 investigational small molecule targeting focal segmental glomerulosclerosis, a rare kidney disease [3] - BioMarin develops and commercializes therapies for life-threatening rare diseases and medical conditions across various regions including the US, Europe, and Asia Pacific [4]